AMDA – The Society for Post-Acute and Long-Term Care Medicine is compelled to comment on the
recent approval of the controversial parenteral Alzheimer’s Dementia (AD) medication, aducanumab.
After considering the evidence, we conclude that the aducanumab trials did not adequately demonstrate
safety or efficacy. Moreover, aducanumab has only been studied in individuals with mild cognitive
impairment or early stage dementia due to hyperamyloidosis (e.g., AD) and has never been tested in a
population representative of nursing home residents. We therefore cannot endorse recommending or
prescribing aducanumab to post-acute and long-term care (PALTC) residents and patients.
recent approval of the controversial parenteral Alzheimer’s Dementia (AD) medication, aducanumab.
After considering the evidence, we conclude that the aducanumab trials did not adequately demonstrate
safety or efficacy. Moreover, aducanumab has only been studied in individuals with mild cognitive
impairment or early stage dementia due to hyperamyloidosis (e.g., AD) and has never been tested in a
population representative of nursing home residents. We therefore cannot endorse recommending or
prescribing aducanumab to post-acute and long-term care (PALTC) residents and patients.
Full Comment here -→ https://drive.google.com/file/d/1dLZkW5586BoLIV0_TsGJxUDbzHGMr8-f/view?usp=sharing